Financial Data and Key Metrics Changes - Vicor recorded product revenues, licensing income, and a patent litigation settlement for Q2 of $141 million, up 50.1% sequentially from $94 million in Q1 2025 and up 64.3% from $85.9 million in Q2 2024 [7] - The gross profit margin for Q2 was 65.3%, an increase of 1810 basis points from the prior quarter, primarily due to the patent litigation settlement [7] - Net income for Q2 totaled $41.2 million, with GAAP diluted income per share at 91 cents based on a fully diluted share count of 45,077,000 shares [9] Business Line Data and Key Metrics Changes - Advanced products revenue increased 1.2% sequentially to $60.6 million, while Brick Products revenue increased 4% sequentially to $35.5 million [7] - Advanced Products' share of total revenue decreased to 63.1% from 63.7% in Q1 2025, with Brick Products' share increasing to 36.9% [7] Market Data and Key Metrics Changes - Shipments to stocking distributors increased 18.9% sequentially but decreased 14.3% year over year [7] - Exports as a percentage of total revenue decreased sequentially to approximately 51.9% from 60.8% in the prior quarter [7] Company Strategy and Development Direction - The company is focused on its top 100 customers and enabling high-performance modular power delivery networks, with next-generation products being sampled to lead customers across four target markets [14] - The strategy includes pursuing additional actions against companies infringing on its intellectual property while continuing to innovate and expand customer engagements [16][19] Management's Comments on Operating Environment and Future Outlook - Management indicated that 2025 is a year of uncertainty and opportunity, with a wide range of possible outcomes for quarterly and annual results [11] - The company expects 2025 to be a record year for revenue, despite uncertainties related to tariffs and market conditions [56][58] Other Important Information - The company reported a cash and cash equivalents total of $338.5 million in Q2, an increase of $42.4 million sequentially [10] - The one-year backlog decreased by 9.6% from the prior quarter, closing at $155.2 million [11] Q&A Session Summary Question: Clarification on the patent litigation settlement and its financial implications - The settlement amount is part of the expected return through 2026, which includes royalties from OEM and hyperscaler licenses [22][24] Question: Book to bill ratio and future bookings trends - Management believes the hesitancy around tariffs is now behind them, and they expect improvements in bookings moving forward [27] Question: Details on order cancellations and affected markets - Cancellations were primarily from the industrial market in China, affecting both older and advanced products [31] Question: Future royalty streams and licensing growth - The company is actively pursuing infringers and expects to see growth in royalty streams as they enforce existing licenses [32] Question: Dynamics of the new licensing settlement - The settlement does not include ongoing royalties, and the company is focused on enforcing its intellectual property rights [39] Question: Progress on Gen five vertical power delivery solutions - The company is on target with the delivery timeline for Gen five solutions to lead customers, with significant progress reported [46][48] Question: Expectations for operating expenses going forward - Operating expenses are expected to remain balanced, with potential lumpiness due to ongoing legal actions [77]

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. (NASDAQ: PIII) (“P3” or the “Company”). (NASDAQ: PIII) Allegations and Investigation Focus: The investigation seeks to determine whether P3 Health Partners, and certain officers and directors, made false a ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased iRobot securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”), of the important August 29, 2025 lead plaintiff deadline. SO WHAT: If you purchased Petco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Fortrea’s business, operations, and prospects, including allegations that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 ea ...

MILWAUKEE, July 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating PharmChem (OTC: PCHM) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcohol Monitoring Systems.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of PharmChem will receive $3.75 per share in cash. PharmChem insiders will recei ...

Core Viewpoint - The Ademi Firm is investigating ZimVie for potential breaches of fiduciary duty and other legal violations related to its transaction with ARCHIMED, which involves a cash offer of $19.00 per share, totaling approximately $730 million in enterprise value [1][2]. Group 1 - ZimVie shareholders are set to receive $19.00 per share in cash, equating to an enterprise value of around $730 million [2]. - The transaction agreement includes provisions that significantly limit competing offers for ZimVie, imposing penalties if a competing bid is accepted [3]. - The investigation focuses on whether the ZimVie board of directors is adequately fulfilling their fiduciary responsibilities to all shareholders amidst these arrangements [3].